TY - JOUR AU - E. Rivero-Ferrer AU - M. Olesen AU - E. Plana AU - J. Aguado AU - N. Saigi-Morgui AU - A. Rubino AU - S. Daoud AU - A. Lei AU - S. Perez-Gutthann AU - T. Schink AU - N. Kristiansen AU - J. Hallas AU - A. Pottegard AU - C. Rebordosa AD - RTI Health Solutions, Pharmacoepidemiology and Risk Management, Av. Diagonal 605, 9-1, 08028, Barcelona, Spain. erivero@rti.org. Department of Public Health, University of Southern Denmark, Clinical Pharmacology, Pharmacy, and Environmental Medicine, Odense, Denmark. RTI Health Solutions, Biostatistics, Barcelona, Spain. RTI Health Solutions, Pharmacoepidemiology and Risk Management, Av. Diagonal 605, 9-1, 08028, Barcelona, Spain. Epidemiology, Respiratory and Immunology, AstraZeneca, Cambridge, UK. BioPharmaceuticals Research and Development, Late-Stage Development Research and Innovation, AstraZeneca, Gaithersburg, MD, USA. Patient Safety Biopharma, Chief Medical Office, AstraZeneca, Barcelona, Spain. Department of Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology-BIPS, Bremen, Germany. AN - 35290649 BT - Clin Drug Investig DO - 10.1007/s40261-022-01120-2 DP - NLM ET - 2022/03/16 LA - eng N1 - 1179-1918 Rivero-Ferrer, Elena Orcid: 0000-0001-5093-2445 Olesen, Morten Orcid: 0000-0002-0937-4952 Plana, Estel Orcid: 0000-0001-8675-7503 Aguado, Jaume Orcid: 0000-0002-9575-0212 Saigí-Morgui, Núria Orcid: 0000-0003-2503-1818 Rubino, Annalisa Daoud, Sami Z Lei, Alejhandra Perez-Gutthann, Susana Orcid: 0000-0001-5798-3691 Schink, Tania Orcid: 0000-0003-2252-1475 Kristiansen, Nina Sahlertz Orcid: 0000-0002-8097-8708 Hallas, Jesper Orcid: 0000-0001-9314-5679 Pottegård, Anton Orcid: 0000-0002-8064-5997 Rebordosa, Cristina Orcid: 0000-0002-0224-1866 Journal Article New Zealand Clin Drug Investig. 2022 Mar 15. doi: 10.1007/s40261-022-01120-2. PY - 2022 SN - 1173-2563 T2 - Clin Drug Investig TI - Characteristics of New Users of Aclidinium Bromide, Aclidinium/Formoterol, and Other COPD Medications in the United Kingdom, Denmark, and Germany ER -